Immunomonitoring of young and elderly stable renal transplantation patients receiving triple immunosuppressive therapy

CHDR0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

试验速览

.A.

•Male or female kidney transplantation patients, 18 to 45 years of age or >60 years of age
•- Patients that have undergone a kidney transplantation > 2 years before study start
•- Patients on maintenance immunosuppression with low-dose prednisolone, MMF and tacrolimus adjusted to target trough levels.
•- Patients that have the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions

•- The use of any medication other than the patient’s standard treatment within less than 5 half-lives prior to study participation, if the investigator judges that it may interfere with the study objectives;
•- The use of immunosuppressive or immunomodulatory medication, other than the patient’s standard treatment, within 3 months before study participation;
•- Any known factor, condition, or disease that might interfere with study conduct or interpretation of the results, in the opinion of the investigator.
•- Unwillingness or inability to comply with the study protocol for any other reason.

发起方